NCT05314400Recruiting
Gadoxetate Abbreviated MRI in Metastatic Colorectal Cancer
A Prospective Study Evaluating Diagnostic Accuracy, Outcome, and Economic Impact of Abbreviated Gadoxetate-enhanced MRI of the Liver in Patients With Metastatic Colorectal Carcinoma
Source: ClinicalTrials.gov · Last updated 11 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
After a patient is diagnosed with colon cancer, they receive a CT of the chest, abdomen, and pelvis to see if the cancer has spread (metastasized) to other parts of the body. A common site for the cancer to spread to is the liver. If an abnormality is seen in the liver on CT, sometimes an MRI of the liver is required to determine a) whether it is cancer or not and b) whether there are small tumours in the liver that were not visible on CT. During the MRI, the patient is injected with intravenous (IV) contrast. This makes liver lesions more conspicuous and also helps determine if they are cancerous or not. The most commonly used IV contrast agent is called Gadovist. However, there is another IV contrast agent called Primovist that is better at detecting liver metastases from colon cancer than Gadovist. This is very important information for surgeons, because if they considering cutting out (resecting) the liver tumours, they want to make sure they get them all. Unfortunately, Primovist is used sparingly in Canadian hospitals because it is more expensive than Gadovist and the MRI takes longer. Some early small studies have suggested that it may be possible to shorten the Primovist MRI significantly (e.g. from 60 minutes to 15 minutes), making it economically feasible to offer Primovist to more patients. However, there have not been any large studies performed to confirm these findings. The purpose of this study is to compare the accuracy of colon cancer liver metastasis detection between a regular, full-length Primovist MRI versus a shortened Primovist MRI protocol. The economic impact will also be assessed.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 17 Mar 2022
- Start date
- 1 Jul 2022
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Diseases
- Colorectal cancer
- NCT number
- NCT05314400
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 Jul 2022 to the primary completion date, 1 Oct 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Documented severe allergic-like reaction gadolinium-based contrast agent
Lab values
- Baseline eGFR of \< 30 mL/min/1.73 m2
Other
- Presence of implanted medical device or metallic object that is MR incompatible
- Severe claustrophobia not relieved by oral anxiolytics
- Weight greater than allowable on MRI table
- Pregnancy
- Diffuse liver metastases, i.e. definitively unresectable
- Severe liver dysfunction, ALBI grade 3
Who the study is looking for
- Male or female, 18 years of age or older
- Diagnosis of colorectal cancer, biopsy proven
- Prior imaging showing liver lesions that may be metastases
- Provision of signed and dated informed consent form
- Willingness to comply with study procedures and availability for the duration of the study
- Able to tolerate MRI required by protocol
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Joseph's Healthcare Coordinator of this site? Confirm its status | London | Canada | Recruiting |
| London Health Sciences Centre Coordinator of this site? Confirm its status | London | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.